Business Wire

Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors

27.4.2023 17:00:00 EEST | Business Wire

Share

Brenus Pharma Announces two groundbreaking presentations on STC-1010, the company's first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma's STC (Stimulated Tumor-Cells) Technology Platform.

Innovative models for anti-tumor vaccine development were highlighted: Inovotion’s CAM (chorioallantoic model) in-ovo assay and Explicyte’s ex-vivo co-cultured assay, were used to characterize the mechanism of action through a specific immune response, and validate the anti-tumor effects of STC-1010.

These models comply with the FDA’s modernization act 2.0 S. 5002 and demonstrate the potential of STC-1010 in clinical settings for the treatment of patients with colorectal cancer.

The first study evaluated the safety and efficacy of STC-1010 in activating the antitumoral immune response against human colorectal adenocarcinoma using the chicken CAM assay. Results obtained in-ovo confirmed the anti-tumor efficacy -mediated by cytokine secretion and T cells expansion- of the vaccine previously observed in CRC syngeneic mouse models. Dendritic cells primed by STC-1010 will induce a multi specific pool of T-lymphocytes against the tumor without toxicity.

The second study evaluated the functional activity of STC-1010-primed dendritic cells (DCs) from PBMCs human donors’ isolation, to activate autologous CD8+ T cells and promote tumor cell death. The study evaluated the cross-priming and specificity of the immune response induced by STC-1010. Results showed that STC-1010 is an efficient strategy to educate the immune system by cross-priming DCs and increasing the activity of specific CD8+ T cells (TCR sequencing) all of which promotes the significant tumor killing observed ex-vivo.

Taken together, these studies provide promising results for the development of the STC-1010 and prove its potential to be presented into clinical setting for the treatment of patients with CRC.

Innovative in vivo model for anti-tumor vaccine development: Safety validation and preliminary efficacy evaluation of a new antitumor vaccine STC-1010 on human colorectal adenocarcinoma using the chicken CAM assay.

Session Title: Clinical Research Excluding Trials - Vaccines

Abstract Presentation Number: 6791

STC-1010 a new therapeutic vaccine promotes tumor cell death.

Session Title: Late-Breaking Research: Immunology 2

Abstract Presentation Number: LB224

For further information:

https://www.brenus-pharma.com/
https://explicyte.com/
https://www.inovotion.com/

1 STC-1010 is a next-generation cancer vaccine immunotherapy that targets tumor antigens and is produced by Allogeneic STC's proprietary Brenus platform. It’s the lead candidate specifically designed to combat colorectal cancer (CRC) including MSS and MSI-H populations in its first line of treatment for the first indication.
2 Inovotion Biopolis- 5 av du Grand Sablon, 38700 La Tronche, France
3 Brenus Pharma Parc industriel Tech Lavaur La Bechade 63 500 Issoire, France
4 Center Georges François Leclerc, 1 rue du Pr Marion 21000 Dijon, France
5 Explicyte 229 Cours de l'Argonne, 33000 Bordeaux
6 Institut Bergonie 229 Cours de l'Argonne, 33000 Bordeaux

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CONTACT BRENUS

Marion Brun
Communication Manager
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72

About Business Wire

Business Wire
Business Wire



http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KLDiscovery Takes Steps to Strengthen Balance Sheet and Long-Term Financial Foundation2.5.2024 23:30:00 EEST | Press release

KLDiscovery Inc. (“KLDiscovery” or the “Company”), a global leader in data management, information governance, eDiscovery, and advisory services solutions, today announced that it has reached an agreement in principle with its principal convertible debenture holders and its principal term loan lender to significantly reduce the Company’s long-term debt and strengthen its financial position, enabling KLDiscovery to focus on its growth model and drive investment in its market-leading client solutions. “Today’s announcement marks an important step forward for our company as we move into the future with a capital structure that supports our industry-leading team and long-term growth and profitability objectives,” said Chris Weiler, Chief Executive Officer of KLDiscovery. “KLDiscovery is a strong business with a leading market position, premier brands, and a clear vision for the future. This agreement underscores our key capital partners’ belief in that vision and will provide our company w

SES AI Reports First Quarter 2024 Earnings Results; Affirms 2024 Outlook2.5.2024 23:15:00 EEST | Press release

SES AI Corporation (“SES AI”) (NYSE: SES), a global leader in the development and manufacturing of high-performance Li-Metal batteries, today announced its first quarter 2024 business results for the period ended March 31, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502964429/en/ The Company posted a Letter to Our Shareholders on its Investor Relations website from Founder and CEO Dr. Qichao Hu and Chief Financial Officer Jing Nealis, which provides a business update and details on first quarter 2024 results. “The game-changing collaboration with Hyundai Motor Company and Kia Corporation is one of the more significant milestones we have reached to date,” stated Dr. Qichao Hu, Founder and CEO. “Moving to the next phase of our contract with these partners, together with other agreements and UAM cell production we are anticipating later this year, reinforces our lead in the race to commercialize our Li-Metal technol

The Indy Autonomous Challenge Returns to the Indianapolis Motor Speedway on September 6, 20242.5.2024 21:00:00 EEST | Press release

The Indy Autonomous Challenge (IAC) will make a grand return to the Indianapolis Motor Speedway (IMS) “The Racing Capital of the World” on September 6th, 2024. The competition is set to be a landmark event, featuring a head-to-head race of the world’s fastest autonomous racecars piloted by AI driver software developed by 10 teams representing 18 top universities from North America, Europe, and Asia. History was made at IMS in October 2021 when IAC organized the world’s first head-to-head high-speed autonomous racing competition. Since then, IAC has organized five races at iconic tracks, including Las Vegas Motor Speedway during CES and the Monza F1 Circuit in Italy. IAC and its university teams have achieved a long list of world records for high-speed ground-based autonomy. World records include the autonomous land speed record (192.2 mph), the top speed on-track (180 mph), the fastest on-track head-to-head overtake (177 mph), and most miles of autonomous racing (7,500 miles). “Three y

Mary Kay Inc. Announces Expansion Into Denmark, Strengthening Its Commitment to Women's Empowerment in Scandinavia2.5.2024 20:07:00 EEST | Press release

Mary Kay Inc., a global beauty brand renowned for its commitment to female empowerment and entrepreneurship, is thrilled to announce that its products will now be sold in Denmark. This strategic move marks a significant milestone in Mary Kay's mission to enrich women's lives across the globe. With this launch, Mary Kay products are now available in all the Scandinavian and Nordic markets in partnership with Lesley Cosmetics, Mary Kay’s authorized distributor in Scandinavia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502841084/en/ Mary Kay Inc., a global beauty brand renowned for its commitment to female empowerment and entrepreneurship, is thrilled to announce that its products will now be sold in Denmark. Denmark, known for its strong focus on gender equality and women's rights, stands as one of the most egalitarian societies in the world, ranking third in the EU on the Gender Equality Index. (Photo: Mary Kay Inc.) D

Interactive Brokers Launches Daily Options on the CAC 40® Index2.5.2024 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the availability of Daily Options on the CAC 40® index, further expanding Interactive Brokers’ robust product suite. Daily Options on the CAC 40® index provide experienced investors with another means to execute short-term trading strategies and manage exposure to the French stock market. Milan Galik, Chief Executive Officer of Interactive Brokers, commented on the launch, "We are pleased to offer Daily Options on the CAC 40® index, which will allow our clients to balance risk and swiftly adjust their portfolios in response to market movements. At Interactive Brokers, we strive to equip our clients with an array of products to find global opportunities, and this new offering underscores our commitment to providing traders with comprehensive product solutions.” Daily Options on the CAC 40® index cater to growing demand from institutional and retail investors for options with daily expirations. The

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye